Literature DB >> 32569831

Off-Label and Unlicensed Drugs in Pediatric Palliative Care: A Prospective Observational Study.

Isabel García-López1, Margarita Cuervas-Mons Vendrell2, Irene Martín Romero3, Iñigo de Noriega3, Juana Benedí González4, Ricardo Martino-Alba3.   

Abstract

CONTEXT: Off-label and unlicensed use of drugs is a widespread practice in pediatric care because of the lack of specific efficacy and safety data and the absence of formulations adapted to the needs of these individuals. Pediatric patients with a life-limiting illness frequently receive drugs under these conditions, although no studies have established the prevalence of this practice.
OBJECTIVES: To describe the prevalence, indications, and most common uses of off-label and unlicensed drugs in a pediatric palliative care unit (PPCU).
METHODS: A prospective cross-sectional observational study carried out between January and October 2019.
RESULTS: About 85 patients involving 1198 prescriptions were analyzed. A total of 39.6% were off label, and 12.9% were unlicensed. All received at least one off-label drug, with a median of five per patient (interquartile range 3-7), and 81.2% received at least one unlicensed drug. A total of 36.1% of the prescriptions were considered off label because of indication, 33.8% because of dosage, and 26.6% because of age. The main drugs used off label were oral morphine, oral levetiracetam, inhaled albuterol, sublingual ondansetron, oral tizanidine, sublingual fentanyl, and oral diazepam. The main symptoms treated with off-label drugs were dyspnea, pain, and nausea/vomiting.
CONCLUSION: More than half of the prescriptions in this PPCU were off label or unlicensed. Treatment indication was one of the main reasons for off-label use. Administration of compounded preparations was common in patients with a life-limiting illness.
Copyright © 2020 American Academy of Hospice and Palliative Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Off-label use; drug approval; drug compounding; drug prescriptions; palliative care; palliative medicine; pediatrics; prevalence

Mesh:

Substances:

Year:  2020        PMID: 32569831     DOI: 10.1016/j.jpainsymman.2020.06.014

Source DB:  PubMed          Journal:  J Pain Symptom Manage        ISSN: 0885-3924            Impact factor:   3.612


  3 in total

1.  Electronic Health Records in Specialized Pediatric Palliative Care: A Qualitative Needs Assessment among Professionals Experienced and Inexperienced in Electronic Documentation.

Authors:  Dorothee Meyer; Sven Kernebeck; Theresa Sophie Busse; Jan Ehlers; Julia Wager; Boris Zernikow; Larissa Alice Dreier
Journal:  Children (Basel)       Date:  2021-03-23

2.  Participatory Design of a Medication Module in an Electronic Medical Record for Paediatric Palliative Care: A Think-Aloud Approach with Nurses and Physicians.

Authors:  Sven Kernebeck; Chantal Jux; Theresa Sophie Busse; Dorothee Meyer; Larissa Alice Dreier; Daniel Zenz; Boris Zernikow; Jan Peter Ehlers
Journal:  Children (Basel)       Date:  2022-01-06

3.  Gaps in Accessibility of Pediatric Formulations: A Cross-Sectional Observational Study of a Teaching Hospital in Northern Thailand.

Authors:  Prangthong Tiengkate; Marc Lallemant; Pimlak Charoenkwan; Chaisiri Angkurawaranon; Penkarn Kanjanarat; Puckwipa Suwannaprom; Phetlada Borriharn
Journal:  Children (Basel)       Date:  2022-02-22
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.